BRAIN Biotech Secures European Patent for CRISPR-BMC Genome-Editing Technology

The European Patent Office has granted BRAIN Biotech a substance patent for its CRISPR-BMC nuclease, designated EP4301852 B1, marking a significant advancement in genome-editing capabilities for industrial applications. This newly patented CRISPR nuclease family, developed through the company's BRAINBioIncubator, exhibits high activity in various prokaryotic and eukaryotic organisms, enabling efficient double-strand breaks at defined genomic locations that facilitate targeted modifications of organism properties.

The BMC® technology allows precise genome editing across a broad spectrum of organisms including bacteria, yeasts, fungi, plants, and mammalian cells. BRAIN Biotech specifically employs this technology to optimize microbial production strains such as E. coli, Bacillus, Pichia, and Aspergillus for manufacturing biomolecules including enzymes, proteins, and small molecules. This patent represents another proprietary CRISPR system alongside the company's existing BEC® nucleases, providing BRAIN Biotech with freedom to utilize the technology for both internal research and customer projects.

Adriaan Moelker, CEO of BRAIN Biotech, emphasized the importance of this patent protection, stating that the technology helps make manufacturing processes utilizing microorganisms more cost-effective. The company offers a business model for technology application across diverse areas and has already granted licenses to companies in various fields, with plans to expand licensing activities. According to Alexander Pelzer, Head of R&D at BRAIN Biotech Zwingenberg, CRISPR-BMC accelerates development of production organisms and strain development for customers through its speed and precision, supported by decades of molecular biology and microbiology experience.

The patent has been effective since March 18, 2026, in all European Unitary Patent countries plus Great Britain and Switzerland, while remaining pending in other key regions including the United States and Japan. Patent protection is being sought for additional nucleases within the BMC® family through selected inventions. This development opens significant potential for commercial application of the patented nucleases, particularly for strain optimization in customer production strains. For more information about the company's broader activities, visit https://www.brain-biotech-group.com.